Topotecan in the therapy of brain metastases in lung cancer

Onkologie

Volumn 21, Issue SUPPL. 4, 1998, Pages 25-27

  Schutte W ^a   Manegold, C ^b   Von Pawel, J V ^c  

^a Stadtisches Krankenhaus Martha Maria   (Germany)

^b Thoraxklinik   (Germany)

^c ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

Brain metastases; Lung cancer; Topotecan

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NAUSEA; NEUTROPENIA; PAIN; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0032428142     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054981     Document Type: Conference Paper

References (9)

1. Glantz MJ, Choy H, Yee L: Prophylactic cranial irradiation in small cell lung cancer: Rationale, results and recommendations. Sem Oncol 1997;24:477-483.
2. Postmus PE, Sleijfer DTh, Haaxma-Reiche H: Chemotherapy of central nervous system metastases from small cell lung cancer. A review. Lung Cancer 1989; 5:254-263.
3. Postmus PE, Haaxma-Reiche H, Gregor A, Groen HJM, Lewinski T, Scolard T, Kirkpatrick A, Curran D, Sahmoud T, Giaccone G: Brain-only metastases of small-cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:29-32.
4. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Jaap V: Topotecan, a new active drug in the second-line-treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. Oncol 1997;15:2090-2096.
5. Schiller JH, von Pawel J, Clarke P, Kleisbauer JP, Dobbs T, Chrysson N, Dane GC, Hudson J, DeWitte M, Fields SZ: Preliminary results of a randomized comparative Phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC). Lung Cancer 1997;18s:13-14.
6. Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippmann SM, Kurie JM, Huber MH, Raber MN, Hong WK: Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996;14:503-513.
7. Herben VMM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet 1996;31:83-102.
8. Baker SD, Heidemann R, Kuttesch JF: CNS penetration of topotecan following continuous infusion in children with cancer. Clin Parmacol Ther 1994;55: 189.
9. Jett JR, Day R, Levitt M, Wolley G, Jacobs S: Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy. Lung Cancer 1997;18s:13.